PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25218815-7	2014	The HDL of ACS patients displayed a limited capacity to mediate cholesterol efflux, especially via the ABCA1-pathway.	Cholesterol	64-75	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	11-14	
23008706-9	2011	Cases with ACS had significant higher values of cortisol, hsCRP, IL-6, fibrinogen, PAI-1, total cholesterol and BMI more than those with stable CAD.	Cholesterol	96-107	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	11-14	
18716006-2	2008	We sought to determine the prevalence and prognostic significance of low HDL cholesterol levels in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS).	Cholesterol	77-88	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	169-172	
19149787-8	2009	nSTE-ACS in comparison to STE-ACS patients were more obese (BMI, P < 0.01), had higher LDL cholesterol (P < 0.01), fasting glucose (P = 0.03).	Cholesterol	94-105	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	5-8	
19151449-18	2008	CONCLUSION: the administration of low-dose curcumin showed a trend of reduction in total cholesterol level and LDL cholesterol level in ACS patients.	Cholesterol	89-100	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	136-139	
19151449-18	2008	CONCLUSION: the administration of low-dose curcumin showed a trend of reduction in total cholesterol level and LDL cholesterol level in ACS patients.	Cholesterol	115-126	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	136-139	
18364141-8	2008	High density lipoprotein-cholesterol levels >1.04 mmol/L were associated with more fibrolipidic ((14.5+/-10.4)% vs (7.1+/-6.5)%, P<0.05) and less necrotic core ((20.6+/-9.7)% vs (27.9+/-12.6)%, P<0.05) percentages in the cohort with ACS.	Cholesterol	25-36	1-aminocyclopropane-1-carboxylate synthase homolog (inactive)	Homo sapiens	242-245